| 白 静,张银福,冯 媱,魏驿欢,同 鑫.纳布啡鞘内注射对糖尿病神经痛模型大鼠行为能力及背根神经节TRPV1表达的影响[J].,2022,(20):3823-3827 |
| 纳布啡鞘内注射对糖尿病神经痛模型大鼠行为能力及背根神经节TRPV1表达的影响 |
| Effects of Intrathecal Injection of Nalbuphine on Behavioral Ability and Expression of TRPV1 in Dorsal Root Ganglia in Diabetic Neuralgia Model Rats |
| 投稿时间：2022-03-06 修订日期：2022-03-31 |
| DOI：10.13241/j.cnki.pmb.2022.20.005 |
| 中文关键词: 纳布啡 鞘内注射 糖尿病神经痛 大鼠 背根神经节 瞬时受体电位V1 |
| 英文关键词: Nalbuphine Intrathecal injection Diabetic neuralgia Rats Dorsal root ganglia Transient receptor potential V1 |
| 基金项目:陕西省自然科学基础研究计划项目（2017JQ8027） |
|
| 摘要点击次数: 672 |
| 全文下载次数: 328 |
| 中文摘要: |
| 摘要 目的：探讨纳布啡鞘内注射对糖尿病神经痛（diabetic neuropathic pain, DNP）模型大鼠行为能力及背根神经节瞬时受体电位V1（transient receptor potential V1，TRPV1）表达的影响。方法：将糖尿病神经痛模型大鼠（n=48）随机平方为三组-模型组、纳布啡1组与纳布啡2组，每组16只。纳布啡1组与纳布啡2组分别给予纳布啡鞘内注射0.5 μg/10 μL与1.0 μg/10 μL，模型组给予注射等剂量的0.9 %氯化钠溶液，每天1次。分别于治疗第7 d、第14 d，采用血糖仪测定与记录空腹血糖（fasting blood glucose，FBG）水平并进行机械痛阈检测；治疗第14 d、第28 d，采用酶联免疫法检测血清IL-6与TNF-α含量，采用免疫印迹法检测背根神经节TRPV1蛋白的相对表达。结果：模型组、纳布啡1组与纳布啡2组治疗第7 d、第14 d的空腹血糖水平都高于20.00 mmol/L，组内与组间对比差异不具有统计学意义（P>0.05）。纳布啡1组与纳布啡2组治疗第7 d、第14 d的机械痛阈高于模型组（P<0.05），也高于治疗前（P<0.05），纳布啡2组与纳布啡1组差异具有统计学意义（P<0.05）。纳布啡1组与纳布啡2组治疗第14 d、第28 d的血清白细胞介素（Interleukin，IL）-6与肿瘤坏死因子（Tumor necrosis factor，TNF）-α含量明显低于模型组（P<0.05），纳布啡2组明显低于纳布啡1组（P<0.05）。纳布啡1组与纳布啡2组治疗第14 d、第28 d的背根神经节TRPV1相对表达水平明显低于模型组（P<0.05），纳布啡2组明显低于纳布啡1组（P<0.05）。结论：纳布啡鞘内注射在糖尿病神经痛模型大鼠的应用能改善行为能力，抑制背根神经节TRPV1的表达，还可抑制血清IL-6与TNF-α的释放，从而发挥镇痛治疗效用。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of intrathecal injection of nalbuphine on the behavioral ability and the expression of transient receptor potential V1 (TRPV1) in the dorsal root ganglion of diabetic neuralgia model rats. Methods: The diabetic neuralgia model rats (n=48) were randomly divided into three groups - model group, nalbuphine group 1 and nalbuphine group 2, with 16 rats in each groups. The nalbuphine group 1 and the nalbuphine group 2 were given intrathecal injection of 0.5 μg/10 μL and 1.0 μg/10 μL of nalbuphine respectively, and the model group were given an equal dose of 0.9 % sodium chloride solution, once a day, On the 7th and 14th days of treatment, the fasting blood glucose (FBG) level was measured and recorded with a blood glucose meter, and the mechanical pain threshold was detected; On the 14th and 28th days of treatment, the serum levels of IL-6 and TNF-α were detected by enzyme-linked immunosorbent assay, and the relative expression of TRPV1 protein in the dorsal root ganglia was detected by western blotting. Results: The fasting blood glucose levels of the model group, nalbuphine group 1 and nalbuphine group 2 were all higher than 20.00 mmol/L on the 7th and 14th days of treatment, and the differences between the groups were not statistically significant(P>0.05). The mechanical pain threshold of nalbuphine group 1 and nalbuphine group 2 on the 7th and 14 th days of treatment were higher than that of the model group (P<0.05), and were also higher than that before treatment (P<0.05). The difference between the nalbuphine 2 group and the nalbuphine 1 group was statistically significant(P<0.05). The levels of serum interleukin (IL)-6 and tumor necrosis factor (TNF)-α in the nalbuphine 1 group and the nalbuphine 2 group on the 14 th and 28 th days of treatment were significantly lower than those in the model group (P<0.05), the nalbuphine 2 group were significantly lower than the nalbuphine 1 group (P<0.05). The relative expression levels of TRPV1 in the dorsal root ganglia of the nalbuphine group 1 and nalbuphine group 2 on the 14 th and 28 th days of treatment were significantly lower than those in the model group (P<0.05), and the nalbuphine group 2 were significantly lower than the nalbuphine group 1(P<0.05). Conclusion: The application of intrathecal injection of nalbuphine in diabetic neuralgia model rats can improve behavioral ability, inhibit the expression of TRPV1 in the dorsal root ganglion, and also inhibit the release of serum IL-6 and TNF-α, thereby exerting analgesic treatment. utility. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
